Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Bayer starts using Pinterest

Becomes first big pharma company to join the up-and-coming social network

Pharma company Bayer on Pinterest

Bayer has joined up-and-coming social network Pinterest and is using it to share images and information about its activities in the US.

Pinterest, which acts as an online pin-board, was launched in 2010 and rapidly began gaining popularity towards the end of 2011. In January 2012 it received 11.7m unique visitors, making it the fastest social media site to break the 10m unique visitor mark.

“Social media platforms like Pinterest provide another way for Bayer to communicate and collaborate about its business and activities including, but not limited to, the topics of innovation, sustainability, business activities, corporate social responsibility, events and leadership,” the company said.

Pinterest allows users to organise and share interesting things they find online through image 'pins' that are organised on 'pinboards'.

In common with more established social networks like Tumblr, which also has great visual appeal, Pinterest users can subscribe to other users' pinboards and 're-pin' content they want to share with their own network.

Bayer's Pinterest debut on the social network makes it the first big pharma company to start using the site, where it joins Menarini's Spanish operations.

Meanwhile, Novo Nordisk has registered its own account to claim its brand, something may want to consider. As the Pharma Marketing Blog points out, several other pharma company names are already being used, including GSK, Roche Merck and JNJ.

5th April 2012

From: Marketing

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics